MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conference:
- 42nd Annual J.P. Morgan Healthcare Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate overview on Thursday, January 11, 2024, at 7:30 am PT. Management will also participate in one-on-one meetings.
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The
Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic
domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic
collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are
trademarks or registered trademarks of MacroGenics, Inc.
Lesen Sie auch
###
CONTACT: CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com